Clinical Trial Update: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating romiplostim for chemotherapy-induced thrombocytopenia in adults with non-small cell lung cancer, ovarian cancer, or breast cancer is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Thrombocytopenia
• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Amgen | Conditions: Chemotherapy-induced Thrombocytopenia | Phase 3 | Status: ACTIVE_NOT_RECRUITING